Plasma Apelin and ADMA Levels in Patients with Essential Hypertension

被引：110

作者：

Sonmez, Alper ^{[1
]}

Celebi, Gurkan ^{[2
]}

Erdem, Gokhan ^{[2
]}

Tapan, Serkan ^{[3
]}

Genc, Halil ^{[2
]}

Tasci, Ilker ^{[2
]}

Ercin, Cemal Nuri ^{[4
]}

Dogru, Teoman ^{[4
]}

Kilic, Selim ^{[5
]}

Uckaya, Gokhan ^{[1
]}

Yilmaz, Mahmut Ilker ^{[6
]}

Erbil, Mehmet Kemal ^{[3
]}

Kutlu, Mustafa ^{[1
]}

机构：

[1] Gulhane Mil Med Acad, Dept Endocrinol, Ankara, Turkey

[2] Gulhane Mil Med Acad, Dept Internal Med, Ankara, Turkey

[3] Gulhane Mil Med Acad, Dept Biochem, Ankara, Turkey

[4] Gulhane Mil Med Acad, Dept Gastroenterol, Ankara, Turkey

[5] Gulhane Mil Med Acad, Dept Epidemiol, Ankara, Turkey

[6] Gulhane Mil Med Acad, Dept Nephrol, Ankara, Turkey

来源：

CLINICAL AND EXPERIMENTAL HYPERTENSION | 2010年 / 32卷 / 03期

关键词：

apelin; asymetric dymethyl arginine (ADMA); essential hypertension; ENDOGENOUS PEPTIDE LIGAND; TYPE-2; DIABETES-MELLITUS; ORPHAN RECEPTOR APJ; ASYMMETRIC DIMETHYLARGININE; NITRIC-OXIDE; ENDOTHELIAL DYSFUNCTION; INSULIN-RESISTANCE; BLOOD-PRESSURE; RISK-FACTOR; IN-VIVO;

D O I：

10.3109/10641960903254505

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Both apelin and asymetric dymethyl arginine (ADMA) regulate blood pressures. Low apelin and high ADMA levels have been reported in several cardiometabolic disorders. However, there is no data about ADMA and apelin levels in essential hypertension and any relationship between them. We investigated a group of newly diagnosed and untreated 30 young hypertensive men and 30 healthy controls. Apelin levels were significantly lower and the ADMA levels were significantly higher in the patients (p = 0.04 for both). Both ADMA and apelin were related to the systolic blood pressures (SBP) (beta = -0.393, p = 0.003; beta = 0.285, p = 0.03, respectively). Future studies are necessary in order to clearly define the role of ADMA and apelin in the pathogenesis of essential hypertension.

引用

页码：179 / 183

页数：5

共 34 条

[1]

Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus [J].

Abbasi, F ;

Asagmi, T ;

Cooke, JP ;

Lamendola, C ;

McLaughlin, T ;

Reaven, GM ;

Stuehlinger, M ;

Tsao, PS .

AMERICAN JOURNAL OF CARDIOLOGY, 2001, 88 (10) :1201-+

[2]

Asymmetric dimethylarginine (ADMA):: A novel risk factor for endothelial dysfunction -: Its role in hypercholesterolemia [J].

Böger, RH ;

Bode-Böger, SM ;

Szuba, A ;

Tsao, PS ;

Chan, JR ;

Tangphao, O ;

Blaschke, TF ;

Cooke, JP .

CIRCULATION, 1998, 98 (18) :1842-1847

[3]

Apelin, a newly identified adipokine up-regulated by insulin and obesity [J].

Boucher, J ;

Masri, B ;

Daviaud, D ;

Gesta, S ;

Guigné, C ;

Mazzucotelli, A ;

Castan-Laurell, I ;

Tack, I ;

Knibiehler, B ;

Carpéné, C ;

Audigier, Y ;

Saulnier-Blache, JS ;

Valet, P .

ENDOCRINOLOGY, 2005, 146 (04) :1764-1771

[4]

Venous dilator effect of apelin, an endogenous peptide ligand for the orphan APJ receptor, in conscious rats [J].

Cheng, X ;

Cheng, XS ;

Pang, CCY .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2003, 470 (03) :171-175

[5]

ADMA: its role in vascular disease [J].

Cooke, JP .

VASCULAR MEDICINE, 2005, 10 :S11-S17

[6]

Low plasma apelin levels in newly diagnosed type 2 diabetes mellitus [J].

Erdem, G. ;

Dogru, T. ;

Tasci, I. ;

Sonmez, A. ;

Tapan, S. .

EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2008, 116 (05) :289-292

[7]

Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure [J].

Földes, G ;

Horkay, F ;

Szokodi, I ;

Vuolteenaho, O ;

Ilves, M ;

Lindstedt, A ;

Mäyränpää, M ;

Sármán, B ;

Seres, L ;

Skoumal, R ;

Lakó-Futó, Z ;

deChâtel, R ;

Ruskoaho, H ;

Tóth, M .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 308 (03) :480-485

[8]

FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499

[9]

Apelin: A new plasma marker of cardiopulmonary disease [J].

Goetze, JP ;

Rehfeld, JF ;

Carlsen, J ;

Videbaek, R ;

Andersen, CB ;

Boesgaard, S ;

Friis-Hansen, L .

REGULATORY PEPTIDES, 2006, 133 (1-3) :134-138

[10]

Hou YC, 1999, CURR PHARM DESIGN, V5, P417

← 1 2 3 4 →